CDK9 and ovarian cancer: Recent work has also highlighted the potential use of tCDK inhibitors in combination with epigenetic drugs, including Bromodomain and Extra-Terminal (BET) motif protein inhibitors (e.g., JQ1, which synergises with CDK7 inhibition in models of ovarian cancer [98], neuroblastoma [99], and iBET-151, which synergises with CDK9 inhibition in models of leukaemia [100]), and histone deacetylase inhibitors (e.g., panobinostat, which synergised with THZ1 in models of diffuse intrinsic pontine glioma [101]).